Get the Stockscreener App
2.32
2.65%
0.06
Cardiff Oncology Inc stock is traded at $2.32, with a volume of 1.02M.
It is up +2.65% in the last 24 hours and down -38.62% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$2.26
Open:
$2.26
24h Volume:
1.02M
Relative Volume:
0.57
Market Cap:
$154.34M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.4946
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
-4.92%
1M Performance:
-38.62%
6M Performance:
-51.16%
1Y Performance:
+1.31%
1-Day Range:
$2.26
$2.3854
1-Week Range:
$2.215
$2.56
52-Week Range:
$2.09
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.32 | 161.66M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Breakout Traders Target Cardiff Oncology Inc. on Recovery Setup2025 Major Catalysts & Reliable Trade Execution Plans - beatles.ru
Is Cardiff Oncology Inc. the Top Chart Pick This WeekDollar Strength & Expert Verified Movement Alerts - kangso.co.kr
Cardiff Oncology Inc. Trading Near Value Zone — Recovery AheadWeekly Trend Recap & AI Powered Buy and Sell Recommendations - 선데이타임즈
Published on: 2025-08-19 02:38:05 - newsimpact.co.kr
Does Cardiff Oncology Inc. qualify in momentum factor screeningMarket Risk Report & Long-Term Growth Stock Strategies - Newser
Forecasting Cardiff Oncology Inc. price range with options data2025 Technical Patterns & AI Driven Price Predictions - Newser
Published on: 2025-08-15 06:29:30 - newsyoung.net
How Cardiff Oncology Inc. stock performs during market volatilityTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Long-Term Safety Investment Analysis Report - Newser
Institutional Tools Highlight Unusual Flow in Cardiff Oncology Inc.Quick Gain Stock Watch With Indicators Reviewed - beatles.ru
Clinical trial by SD company proves promising for drug that targets colorectal cancer - NewsBreak: Local News & Alerts
Q3 EPS Forecast for Cardiff Oncology Decreased by Analyst - Defense World
Analyzing drawdowns of Cardiff Oncology Inc. with statistical toolsDaily Technical Forecast for Quick Gains - Newser
Has Cardiff Oncology Inc. found a price floorReliable Setup Screener with Low Risk - Newser
What earnings revisions data tells us about Cardiff Oncology Inc.Minimal Risk Growth Investment Opportunity Analysis - Newser
Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday - Defense World
Cardiff Oncology Price Target Cut to $10 by H.C. Wainwright. - AInvest
H.C. Wainwright lowers Cardiff Oncology stock price target on trial data - Investing.com Nigeria
Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom - insights.citeline.com
How does Cardiff Oncology Inc. generate profit in a changing economyAchieve breakthrough gains with smart trades - Jammu Links News
What is the dividend policy of Cardiff Oncology Inc. stockGet real-time alerts on top stocks - Jammu Links News
Why is Cardiff Oncology Inc. stock attracting strong analyst attentionFree Popular Stock Recommendations - Jammu Links News
Should I hold or sell Cardiff Oncology Inc. stock in 2025Maximize returns with disciplined investment techniques - Jammu Links News
What institutional investors are buying Cardiff Oncology Inc. stockUnstoppable profit momentum - Jammu Links News
Is Cardiff Oncology Inc. stock overvalued or undervaluedMarket-crushing stock picks - Jammu Links News
How strong is Cardiff Oncology Inc. company’s balance sheetFree Risk Assessment Services - Jammu Links News
What analysts say about Cardiff Oncology Inc. stockGrow your wealth with proven stock picks - Jammu Links News
What drives Cardiff Oncology Inc. stock priceUnrivaled growth potential - Jammu Links News
What is the risk reward ratio of investing in Cardiff Oncology Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What catalysts could drive Cardiff Oncology Inc. stock higher in 2025Free Investment Risk Control - Jammu Links News
Is Cardiff Oncology Inc. a good long term investmentHigh-return market picks - Jammu Links News
When is Cardiff Oncology Inc. stock expected to show significant growthSuperior returns - Jammu Links News
Is Cardiff Oncology Inc. a growth stock or a value stockNavigate the market with precision tools - Jammu Links News
William Blair Raises Earnings Estimates for Cardiff Oncology - Defense World
Friday 8/1 Insider Buying Report: CRDF, MBIN - Nasdaq
Both Individual Investors Who Control a Good Portion of Cardiff Oncology, Inc. (NASDAQ:CRDF) Along With Institutions Must Be Dismayed After Last Week's 42% Decrease - 富途牛牛
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - inkl
Cardiff Oncology Insiders Land Bargain With Gains Of US$244k - Yahoo Finance
Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
Cardiff Oncology (CRDF.O) Plummets 27%: What's Behind the Sharp Intraday Move? - AInvest
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Cardiff Oncology Shares Slide Over 26% In Premarket Trading After Mixed Q2 - Benzinga
Cardiff Oncology Plunges 26.59% on Earnings Miss - AInvest
Cardiff Oncology 2025 Q2 Earnings Financial Struggles as Net Income Declines 18.4% - AInvest
Cardiff Oncology Reports Q2 2025 Financial Results - TipRanks
Cardiff Oncology shares fall 26.89% after-hours after reporting a wider Q2 net loss. - AInvest
Cardiff Oncology shares plunge after Q2 earnings miss By Investing.com - Investing.com South Africa
Cardiff Oncology Announces Positive Data From Ongoing Randomized Phase 2 First-Line Ras-Mutated Mcrc Clinical Trial (Crdf-004) - TradingView
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Cardiff Oncology: Q2 Earnings Snapshot - San Francisco Chronicle
Cardiff Oncology earnings missed by $0.02, revenue topped estimates - Investing.com
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
| Levine James E. | Chief Financial Officer |
Dec 17 '24 |
Buy |
5.42 |
2,752 |
14,905 |
65,316 |
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):